X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ARCT-032 utilizes Arcturus' LUNAR® lipid-mediated aerosolized platform to deliver CFTR messenger RNA to the lungs. It is under phase 1 clinical development for the treatment of Cystic Fibrosis.
Lead Product(s): ARCT-032
Therapeutic Area: Genetic Disease Product Name: ARCT-032
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2024
Details:
ARCT-154 is an self-amplifying mRNA (sa-mRNA) vaccine based on the SARS-CoV-2 D614G variant spike protein. This covid-19 vaccine for initial vaccination and booster for adults 18 years and older.
Lead Product(s): ARCT-154
Therapeutic Area: Infections and Infectious Diseases Product Name: LUNAR-COV19
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: CSL
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 28, 2023
Details:
ARCT-032 utilizes Arcturus' LUNAR® lipid-mediated aerosolized platform to deliver CFTR messenger RNA to the lungs. It is under phase 1 clinical development for the treatment of Cystic Fibrosis.
Lead Product(s): ARCT-032
Therapeutic Area: Genetic Disease Product Name: ARCT-032
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
The funding will advance ARCT-032, a novel messenger RNA (mRNA) therapeutic candidate formulated with Arcturus’ LUNAR® delivery technology for the treatment of Cystic Fibrosis.
Lead Product(s): ARCT-032
Therapeutic Area: Genetic Disease Product Name: ARCT-032
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 26, 2023
Details:
ARCT-154, a next generation mRNA vaccine, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. The companies (Arcturus and CSL Seqirus) anticipate an approval decision by the European Commission in 2024.
Lead Product(s): ARCT-154
Therapeutic Area: Infections and Infectious Diseases Product Name: ARCT-154
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: CSL
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
ARCT-810 is a development candidate that represents a novel approach to treat ornithine transcarbamylase deficiency and FDA has granted Fast Track Designation.
Lead Product(s): ARCT-810
Therapeutic Area: Genetic Disease Product Name: ARCT-810
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
ARCT-032 delivers CFTR messenger RNA to the lungs. Expression of a functional copy of the CFTR mRNA in the lungs of people with CF has the potential to restore CFTR activity and mitigate the downstream effects that cause progressive lung disease. T
Lead Product(s): ARCT-032
Therapeutic Area: Genetic Disease Product Name: ARCT-032
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2023
Details:
ARCT-154, a Self-amplifying mRNA vaccines promise the flexibility of plasmid DNA vaccines with enhanced immunogenicity and safety. Under the agreement, CSL will have the exclusive license to Arcturus’ next generation mRNA technology in the fields of influenza and COVID-19.
Lead Product(s): ARCT-154
Therapeutic Area: Infections and Infectious Diseases Product Name: ARCT-154
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: CSL
Deal Size: $4,500.0 million Upfront Cash: $200.0 million
Deal Type: Termination December 12, 2022
Details:
The new results demonstrate broad neutralizing antibody response against Omicron variants of concern, including BA.5, lasting for up to at least six months after administration of low-dose (5 mcg) ARCT-154 booster.
Lead Product(s): ARCT-154
Therapeutic Area: Infections and Infectious Diseases Product Name: ARCT-154
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Details:
Three-month data from LUNAR-COV19 (ARCT-154) booster trial showed meaningful and persistent increase of neutralizing antibody activity against multiple variants of SARS-CoV-2.
Lead Product(s): ARCT-154
Therapeutic Area: Infections and Infectious Diseases Product Name: LUNAR-COV19
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
